The Experts below are selected from a list of 90 Experts worldwide ranked by ideXlab platform

Judith Berman - One of the best experts on this subject based on the ideXlab platform.

  • Topical Paromomycin/Methylbenzethonium Chloride Plus Parenteral Meglumine Antimonate as Treatment for American Cutaneous Leishmaniasis: Controlled Study
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1998
    Co-Authors: Jaime Soto, P. Fuya, Rogelio Herrera, Judith Berman
    Abstract:

    We determined the efficacy of the combination of the topical formulation 15% paromomycin sulfate/12% Methylbenzethonium Chloride (MBCL) and a short course (7 days) of parenteral meglumine antimonate (pentavalent antimony [Sb]) as treatment of American cutaneous leishmaniasis in Colombian patients. Patients were randomly assigned in unequal allocation (2:1:1:1) to group 1 (topical paromomycin/MBCL plus injectable Sb for 7 days), group 2 (topical placebo plus injectable Sb for 7 days), group 3 (topical paromomycin/MBCL plus injectable Sb for 3 days), and group 4 (injectable Sb for 20 days). Cure was defined as complete reepithelialization of all lesions without relapse. Cure rates among groups were as follows: 58% (34 of 59), group 1; 53% (16 of 30), group 2; 20% (6 of 30), group 3; and 84% (26 of 31), group 4. Seventy-one percent of the organisms identified to the species level were Leishmania braziliensis panamensis. We conclude that 10 days of therapy with paromomycin/MBCL does not augment the response of cutaneous leishmaniasis (predominately due to L. braziliensis panamensis) to a short course of treatment with meglumine antimonate.

  • topical paromomycin Methylbenzethonium Chloride plus parenteral meglumine antimonate as treatment for american cutaneous leishmaniasis controlled study
    Clinical Infectious Diseases, 1998
    Co-Authors: Jaime Soto, P. Fuya, Rogelio Herrera, Judith Berman
    Abstract:

    We determined the efficacy of the combination of the topical formulation 15% paromomycin sulfate/12% Methylbenzethonium Chloride (MBCL) and a short course (7 days) of parenteral meglumine antimonate (pentavalent antimony [Sb]) as treatment of American cutaneous leishmaniasis in Colombian patients. Patients were randomly assigned in unequal allocation (2:1:1:1) to group 1 (topical paromomycin/MBCL plus injectable Sb for 7 days), group 2 (topical placebo plus injectable Sb for 7 days), group 3 (topical paromomycin/MBCL plus injectable Sb for 3 days), and group 4 (injectable Sb for 20 days). Cure was defined as complete reepithelialization of all lesions without relapse. Cure rates among groups were as follows: 58% (34 of 59), group 1; 53% (16 of 30), group 2; 20% (6 of 30), group 3; and 84% (26 of 31), group 4. Seventy-one percent of the organisms identified to the species level were Leishmania braziliensis panamensis. We conclude that 10 days of therapy with paromomycin/MBCL does not augment the response of cutaneous leishmaniasis (predominately due to L. braziliensis panamensis) to a short course of treatment with meglumine antimonate.

  • Successful Treatment of New World Cutaneous Leishmaniasis with a Combination of Topical Paromomycin/Methylbenzethonium Chloride and Injectable Meglumine Antimonate
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1995
    Co-Authors: Jaime Soto, N. Hernandez, H. Mejia, Max Grogl, Judith Berman
    Abstract:

    Colombian patients with New World cutaneous leishmaniasis were treated with a combination of a topical formulation (15% paromomycin sulfate/5% Methylbenzethonium Chloride, twice a day) and parenteral meglumine antimonate (20 mg of antimony [Sb]/[kg.d]). Cohort I received topical therapy for 10 days and Sb for 1 days; 18 (90%) of the 20 patients were cured (follow-up, 12 months). Other clinical data suggested that neither the topical formulation alone nor the 1-day regimen of Sb alone would have cured many patients. In a subsequent cohort, which received topical therapy for 10 days and Sb for 3 days, the cure rate was 42% (eight of 19 patients). In Colombian cohorts (historical controls) treated with Sb alone for 10-15 days, the cure rate was 31%-36%. Side effects in cohort 1 patients consisted of local reactions to the topical formulation: burning and pruritis in 25% of patients and vesicle formation in 15% of patients. This is the first report that a regimen partially composed of topical antimicrobial agents can be highly effective for treatment of New World cutaneous leishmaniasis

  • successful treatment of new world cutaneous leishmaniasis with a combination of topical paromomycin Methylbenzethonium Chloride and injectable meglumine antimonate
    Clinical Infectious Diseases, 1995
    Co-Authors: Jaime Soto, N. Hernandez, H. Mejia, Max Grogl, Judith Berman
    Abstract:

    Colombian patients with New World cutaneous leishmaniasis were treated with a combination of a topical formulation (15% paromomycin sulfate/5% Methylbenzethonium Chloride, twice a day) and parenteral meglumine antimonate (20 mg of antimony [Sb]/[kg.d]). Cohort I received topical therapy for 10 days and Sb for 1 days; 18 (90%) of the 20 patients were cured (follow-up, 12 months). Other clinical data suggested that neither the topical formulation alone nor the 1-day regimen of Sb alone would have cured many patients. In a subsequent cohort, which received topical therapy for 10 days and Sb for 3 days, the cure rate was 42% (eight of 19 patients). In Colombian cohorts (historical controls) treated with Sb alone for 10-15 days, the cure rate was 31%-36%. Side effects in cohort 1 patients consisted of local reactions to the topical formulation: burning and pruritis in 25% of patients and vesicle formation in 15% of patients. This is the first report that a regimen partially composed of topical antimicrobial agents can be highly effective for treatment of New World cutaneous leishmaniasis

Jaime Soto - One of the best experts on this subject based on the ideXlab platform.

  • Topical Paromomycin/Methylbenzethonium Chloride Plus Parenteral Meglumine Antimonate as Treatment for American Cutaneous Leishmaniasis: Controlled Study
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1998
    Co-Authors: Jaime Soto, P. Fuya, Rogelio Herrera, Judith Berman
    Abstract:

    We determined the efficacy of the combination of the topical formulation 15% paromomycin sulfate/12% Methylbenzethonium Chloride (MBCL) and a short course (7 days) of parenteral meglumine antimonate (pentavalent antimony [Sb]) as treatment of American cutaneous leishmaniasis in Colombian patients. Patients were randomly assigned in unequal allocation (2:1:1:1) to group 1 (topical paromomycin/MBCL plus injectable Sb for 7 days), group 2 (topical placebo plus injectable Sb for 7 days), group 3 (topical paromomycin/MBCL plus injectable Sb for 3 days), and group 4 (injectable Sb for 20 days). Cure was defined as complete reepithelialization of all lesions without relapse. Cure rates among groups were as follows: 58% (34 of 59), group 1; 53% (16 of 30), group 2; 20% (6 of 30), group 3; and 84% (26 of 31), group 4. Seventy-one percent of the organisms identified to the species level were Leishmania braziliensis panamensis. We conclude that 10 days of therapy with paromomycin/MBCL does not augment the response of cutaneous leishmaniasis (predominately due to L. braziliensis panamensis) to a short course of treatment with meglumine antimonate.

  • topical paromomycin Methylbenzethonium Chloride plus parenteral meglumine antimonate as treatment for american cutaneous leishmaniasis controlled study
    Clinical Infectious Diseases, 1998
    Co-Authors: Jaime Soto, P. Fuya, Rogelio Herrera, Judith Berman
    Abstract:

    We determined the efficacy of the combination of the topical formulation 15% paromomycin sulfate/12% Methylbenzethonium Chloride (MBCL) and a short course (7 days) of parenteral meglumine antimonate (pentavalent antimony [Sb]) as treatment of American cutaneous leishmaniasis in Colombian patients. Patients were randomly assigned in unequal allocation (2:1:1:1) to group 1 (topical paromomycin/MBCL plus injectable Sb for 7 days), group 2 (topical placebo plus injectable Sb for 7 days), group 3 (topical paromomycin/MBCL plus injectable Sb for 3 days), and group 4 (injectable Sb for 20 days). Cure was defined as complete reepithelialization of all lesions without relapse. Cure rates among groups were as follows: 58% (34 of 59), group 1; 53% (16 of 30), group 2; 20% (6 of 30), group 3; and 84% (26 of 31), group 4. Seventy-one percent of the organisms identified to the species level were Leishmania braziliensis panamensis. We conclude that 10 days of therapy with paromomycin/MBCL does not augment the response of cutaneous leishmaniasis (predominately due to L. braziliensis panamensis) to a short course of treatment with meglumine antimonate.

  • Successful Treatment of New World Cutaneous Leishmaniasis with a Combination of Topical Paromomycin/Methylbenzethonium Chloride and Injectable Meglumine Antimonate
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1995
    Co-Authors: Jaime Soto, N. Hernandez, H. Mejia, Max Grogl, Judith Berman
    Abstract:

    Colombian patients with New World cutaneous leishmaniasis were treated with a combination of a topical formulation (15% paromomycin sulfate/5% Methylbenzethonium Chloride, twice a day) and parenteral meglumine antimonate (20 mg of antimony [Sb]/[kg.d]). Cohort I received topical therapy for 10 days and Sb for 1 days; 18 (90%) of the 20 patients were cured (follow-up, 12 months). Other clinical data suggested that neither the topical formulation alone nor the 1-day regimen of Sb alone would have cured many patients. In a subsequent cohort, which received topical therapy for 10 days and Sb for 3 days, the cure rate was 42% (eight of 19 patients). In Colombian cohorts (historical controls) treated with Sb alone for 10-15 days, the cure rate was 31%-36%. Side effects in cohort 1 patients consisted of local reactions to the topical formulation: burning and pruritis in 25% of patients and vesicle formation in 15% of patients. This is the first report that a regimen partially composed of topical antimicrobial agents can be highly effective for treatment of New World cutaneous leishmaniasis

  • successful treatment of new world cutaneous leishmaniasis with a combination of topical paromomycin Methylbenzethonium Chloride and injectable meglumine antimonate
    Clinical Infectious Diseases, 1995
    Co-Authors: Jaime Soto, N. Hernandez, H. Mejia, Max Grogl, Judith Berman
    Abstract:

    Colombian patients with New World cutaneous leishmaniasis were treated with a combination of a topical formulation (15% paromomycin sulfate/5% Methylbenzethonium Chloride, twice a day) and parenteral meglumine antimonate (20 mg of antimony [Sb]/[kg.d]). Cohort I received topical therapy for 10 days and Sb for 1 days; 18 (90%) of the 20 patients were cured (follow-up, 12 months). Other clinical data suggested that neither the topical formulation alone nor the 1-day regimen of Sb alone would have cured many patients. In a subsequent cohort, which received topical therapy for 10 days and Sb for 3 days, the cure rate was 42% (eight of 19 patients). In Colombian cohorts (historical controls) treated with Sb alone for 10-15 days, the cure rate was 31%-36%. Side effects in cohort 1 patients consisted of local reactions to the topical formulation: burning and pruritis in 25% of patients and vesicle formation in 15% of patients. This is the first report that a regimen partially composed of topical antimicrobial agents can be highly effective for treatment of New World cutaneous leishmaniasis

Louis Weinrauch - One of the best experts on this subject based on the ideXlab platform.

  • Topical treatment of New World cutaneous leishmaniasis in Belize: A clinical study
    Journal of the American Academy of Dermatology, 1993
    Co-Authors: Louis Weinrauch, Filiberto Cawich, Peter Craig, St. John Xavier Sosa
    Abstract:

    Background : Many studies have been performed during the past decade to find an effective topical therapy for cutaneous leishmaniasis (CL). Objective : Our purpose was to evaluate the effect of paromomycin ointment (P-ointment) containing 15% paromomycin sulfate and 12% Methylbenzethonium Chloride on Belizean patients with New World CL. Methods : Fifty-three patients were treated twice daily for 14 to 21 days with P-ointment. Results : Sixty-eight percent of the patients healed, 6% had a delayed cure, and 26% did not respond. No toxic effects from the ointment were observed. Conclusion : Topical paromomycin is as efficacious in the treatment of New World CL as other currently accepted modalities that are potentially more toxic.

  • Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: A double-blind control study
    Journal of the American Academy of Dermatology, 1992
    Co-Authors: Sima Halevy, M H Grunwald, Louis Weinrauch
    Abstract:

    Background: A controlled study of the efficacy of topical paromomycin sulfate (PR) and Methylbenzethonium Chloride (MBCI) in cutaneous leishmaniasis (CL) has not yet been performed. Objective: The therapeutic effect of an ointment containing 15% PR and either 12% or 5% MBCI (15/12 or 15/5 P-ointment) on patients suffering from Old World CL was examined in a randomized, double-blind, cross-over study. Methods: Thirty-nine patients with Old World CL caused by Leishmania major were treated topically, twice daily, for 10 to 20 days with 15/12 or 15/5 P-ointment and 10 to 20 days with a placebo ointment to achieve a total of 30 days of treatment in all groups. Results: In the P-ointment-treated groups, 74.2% (29 of 39 patients) of the patients were cured versus 26.6% (4 of 15 patients) in the placebo-treated group. Little difference was found between the 15/12 and 15/5 P-ointment groups. Conclusion: In most of the patients treated with the active ingredients, total elimination of the parasites was achieved within the first 10 days of treatment.

Sima Halevy - One of the best experts on this subject based on the ideXlab platform.

  • Cell-mediated immune response in cutaneous leishmaniasis patients
    European Journal of Dermatology, 1996
    Co-Authors: Dafna Hallel-halevy, A. Kharebov, R. Sneier, Sima Halevy
    Abstract:

    The aim of this study was to evaluate the cell-mediated immune response in cutaneous leishmaniasis (CL) patients, its usefulness as a diagnostic tool and to examine its variability in relation to chemotherapeutic treatment. Cell-mediated immunity was evaluated by a lymphocyte proliferation (LP) assay using whole blood specimens collected from 68, CL patients. Forty of them were treated topically with paromomycin plus Methylbenzethonium Chloride ointment ± systemic allopurinol, and tested before and after termination of treatment. The LP assay was positive in 86%-100% of the untreated patients at the time of referral. Treatment given at various intervals after infection neither altered, nor terminated the development of cellular immune response. A fluctuation of the immune response was observed in 4 patients during infection. Therefore, we conclude that the LP response becomes positive very early after infection, and can be used as an additional diagnostic tool for CL. No correlation was demonstrated between the level of LP and the result of treatment.

  • Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: A double-blind control study
    Journal of the American Academy of Dermatology, 1992
    Co-Authors: Sima Halevy, M H Grunwald, Louis Weinrauch
    Abstract:

    Background: A controlled study of the efficacy of topical paromomycin sulfate (PR) and Methylbenzethonium Chloride (MBCI) in cutaneous leishmaniasis (CL) has not yet been performed. Objective: The therapeutic effect of an ointment containing 15% PR and either 12% or 5% MBCI (15/12 or 15/5 P-ointment) on patients suffering from Old World CL was examined in a randomized, double-blind, cross-over study. Methods: Thirty-nine patients with Old World CL caused by Leishmania major were treated topically, twice daily, for 10 to 20 days with 15/12 or 15/5 P-ointment and 10 to 20 days with a placebo ointment to achieve a total of 30 days of treatment in all groups. Results: In the P-ointment-treated groups, 74.2% (29 of 39 patients) of the patients were cured versus 26.6% (4 of 15 patients) in the placebo-treated group. Little difference was found between the 15/12 and 15/5 P-ointment groups. Conclusion: In most of the patients treated with the active ingredients, total elimination of the parasites was achieved within the first 10 days of treatment.

Max Grogl - One of the best experts on this subject based on the ideXlab platform.

  • Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin.
    The Journal of parasitology, 1999
    Co-Authors: Max Grogl, Brian G. Schuster, William Ellis, Jonathan D. Berman
    Abstract:

    Cutaneous leishmaniasis is presently treated with 20 days of parenteral therapy with a frequently toxic drug (antimony). Topical formulations of paromomycin (15%) plus Methylbenzethonium Chloride (MBCL, 12%) or plus urea (10%) in soft white paraffin have been tested for Old and New World disease in humans. We compared the efficacy of a new topical formulation, WR 279,396 (paromomycin [15%] plus gentamicin [0.5%]) to the clinical formulations in the treatment of cutaneous disease in BALB/c mice. Sixty-day-old lesions were treated twice a day for 10 days, and the response to therapy was determined over a further 70 days. For ulcers due to Leishmania major or to Leishmania mexicana, 100% of lesions in the WR 279,396 group healed by day 20 after therapy and did not relapse by day 70; 83% of lesions healed without relapse in the paromomycin-MBCL group. In the paromomycin-urea group, 100% of L. major lesions healed by day 30 but 30% relapsed. For ulcers due to Leishmania panamensis or Leishmania amazonensis, all lesions treated with WR 279,396 healed and did not relapse; < 50% of lesions treated with paromomycin-MBCL healed by day 30, and all lesions relapsed by day 70. In addition to being active, WR 279,396 was not toxic in this model and appears to have a cosmetic effect (promoting hair growth, healing, and limiting the size of the scar).

  • Successful Treatment of New World Cutaneous Leishmaniasis with a Combination of Topical Paromomycin/Methylbenzethonium Chloride and Injectable Meglumine Antimonate
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1995
    Co-Authors: Jaime Soto, N. Hernandez, H. Mejia, Max Grogl, Judith Berman
    Abstract:

    Colombian patients with New World cutaneous leishmaniasis were treated with a combination of a topical formulation (15% paromomycin sulfate/5% Methylbenzethonium Chloride, twice a day) and parenteral meglumine antimonate (20 mg of antimony [Sb]/[kg.d]). Cohort I received topical therapy for 10 days and Sb for 1 days; 18 (90%) of the 20 patients were cured (follow-up, 12 months). Other clinical data suggested that neither the topical formulation alone nor the 1-day regimen of Sb alone would have cured many patients. In a subsequent cohort, which received topical therapy for 10 days and Sb for 3 days, the cure rate was 42% (eight of 19 patients). In Colombian cohorts (historical controls) treated with Sb alone for 10-15 days, the cure rate was 31%-36%. Side effects in cohort 1 patients consisted of local reactions to the topical formulation: burning and pruritis in 25% of patients and vesicle formation in 15% of patients. This is the first report that a regimen partially composed of topical antimicrobial agents can be highly effective for treatment of New World cutaneous leishmaniasis

  • successful treatment of new world cutaneous leishmaniasis with a combination of topical paromomycin Methylbenzethonium Chloride and injectable meglumine antimonate
    Clinical Infectious Diseases, 1995
    Co-Authors: Jaime Soto, N. Hernandez, H. Mejia, Max Grogl, Judith Berman
    Abstract:

    Colombian patients with New World cutaneous leishmaniasis were treated with a combination of a topical formulation (15% paromomycin sulfate/5% Methylbenzethonium Chloride, twice a day) and parenteral meglumine antimonate (20 mg of antimony [Sb]/[kg.d]). Cohort I received topical therapy for 10 days and Sb for 1 days; 18 (90%) of the 20 patients were cured (follow-up, 12 months). Other clinical data suggested that neither the topical formulation alone nor the 1-day regimen of Sb alone would have cured many patients. In a subsequent cohort, which received topical therapy for 10 days and Sb for 3 days, the cure rate was 42% (eight of 19 patients). In Colombian cohorts (historical controls) treated with Sb alone for 10-15 days, the cure rate was 31%-36%. Side effects in cohort 1 patients consisted of local reactions to the topical formulation: burning and pruritis in 25% of patients and vesicle formation in 15% of patients. This is the first report that a regimen partially composed of topical antimicrobial agents can be highly effective for treatment of New World cutaneous leishmaniasis